ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2022

Jul 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2022-07-08

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-08	Common Stock	D	551197	$0.00	Disposed	3508938	Direct

Footnotes

F1: Modification of previously granted award from 800,000 to 248,803.

F2: Includes a total of 1,649,282 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.